BioTryp Therapeutics
Preclinical-stage biotechnology company developing small-molecule therapies that inhibit bacterial biofilm formation. Focused on anti-biofilm compound discovery and medicinal chemistry to create add-on therapeutics for infections with an initial indication in urinary tract infections. Engages in collaborative R&D, grant-funded projects, and industry partnerships to progress candidates toward preclinical development.
Industries
Nr. of Employees
small (1-50)
Products
Biofilm-Inhibiting Small Molecules
A class of small molecules developed to inhibit biofilm formation by targeting bacteria's key defense mechanisms, serving as an add-on therapy to help antibiotics clear infections without driving resistance.
Biofilm-Inhibiting Small Molecules
A class of small molecules developed to inhibit biofilm formation by targeting bacteria's key defense mechanisms, serving as an add-on therapy to help antibiotics clear infections without driving resistance.
Services
Research and development of small-molecule inhibitors of bacterial biofilm formation, including medicinal chemistry, compound synthesis coordination, and in vitro biofilm testing. Delivered through collaborative R&D and partner-led synthesis and design cycles.
Research and development of small-molecule inhibitors of bacterial biofilm formation, including medicinal chemistry, compound synthesis coordination, and in vitro biofilm testing. Delivered through collaborative R&D and partner-led synthesis and design cycles.
Expertise Areas
- Anti-biofilm small-molecule drug discovery
- Medicinal chemistry and lead optimisation
- In vitro biofilm assays and assay development
- Preclinical drug discovery for anti-infectives
Key Technologies
- Small-molecule therapeutics
- Medicinal chemistry
- Lead optimisation
- In vitro biofilm assays
News & Updates
Company delegation participated in an innovation programme across multiple Chinese cities to explore investment and partnership opportunities (May 6-14, 2026).
Independent coverage discussing the company’s science and commercial progress in anti-biofilm therapies.
Raised £300k in pre-seed funding to advance medicinal chemistry and identify promising compounds for preclinical development (investors included QUBIS Innovation Fund, Cambridge Enterprise Ventures, Parkwalk Advisors).
Received advisory services and funding support for a UK-Canada collaborative project to progress compounds into lead optimisation, including CA$200k from NRC IRAP and £300k from Innovate UK.
Recognised among winners of the Impact55 competition for impact-driven startups in the Cambridgeshire region (package of legal support awarded).
Winner of the Angel Prize at the 2025 Trinity Bradfield Prize, recognising commercial progress.
Company delegation participated in an innovation programme across multiple Chinese cities to explore investment and partnership opportunities (May 6-14, 2026).
Independent coverage discussing the company’s science and commercial progress in anti-biofilm therapies.
Raised £300k in pre-seed funding to advance medicinal chemistry and identify promising compounds for preclinical development (investors included QUBIS Innovation Fund, Cambridge Enterprise Ventures, Parkwalk Advisors).
Received advisory services and funding support for a UK-Canada collaborative project to progress compounds into lead optimisation, including CA$200k from NRC IRAP and £300k from Innovate UK.
Recognised among winners of the Impact55 competition for impact-driven startups in the Cambridgeshire region (package of legal support awarded).
Winner of the Angel Prize at the 2025 Trinity Bradfield Prize, recognising commercial progress.